Clinical trials: Metastatic Kidney Carcinoma
Metastatic Renal Cell Carcinoma
Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First-line Therapy
The purpose of this retrospective observational study was to analyze the effect of targeted therapies administered as second-line treatment after failure of pazopanib as well as increase the amount of information available on…
- Trial name
- SPAZO (NCT02282579)
- Testing
- Pazopanib
- Where
- 34 sites in Spain
- Volunteers
- 300 people
- Sponsor
- Spanish Oncology Genito-Urinary Group
Urothelial Carcinoma
A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy
The purpose of this study is to determine the appropriate dose of AEZS-108 to treat patients with a tumor of the urinary system.
- Trial name
- NCT01234519
- Testing
- AEZS-108, AEZS-108 at MTD
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- AEterna Zentaris
Progressive Metastatic Malignancies
Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies
This is a Phase 1, open-labeled, non-randomized, multi-center, competitive enrollment and dose-escalation study of ALT-801, the study drug.
- Trial name
- NCT00496860
- Testing
- ALT-801
- Where
- 4 sites in United States
- Volunteers
- 26 people
- Sponsor
- Altor BioScience
Cancer, Metastatic Melanoma
NOTION: iN-home Sampling Of cyTokines in ImmunOtherapy patieNts
This study will explore the ability of patients on first line combination immunotherapy to sample cytokines at home. The data from this study will be used to evaluate the feasibility of in-home testing and the ability to analyse…
- Conditions
- Cancer, Metastatic Melanoma, Renal Cell Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT04960059
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 24 people
- Sponsor
- The Christie NHS Foundation Trust
Renal Cell Carcinoma Metastatic
Combined Aerobic and Resistance Exercise Training in Metastatic Renal Cell Carcinoma
The trial studies the effects of personalized home-based aerobic and resistance exercises on quality of life, changes in physical activity levels, and the change in inflammatory myokines with the exercise intervention in…
- Trial name
- NCT05103722
- Testing
- Combined Aerobic and Resistance Exercise Training
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Bladder Squamous Cell Carcinoma, Locally Advanced Bladder Carcinoma
Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology
This phase II trial tests how well enfortumab vedotin (EV) and pembrolizumab works in treating patients with bladder cancer of variant histology (a group of less common types of bladder cancer) that have spread to nearby tissue…
- Conditions
- Bladder Squamous Cell Carcinoma, Locally Advanced Bladder Carcinoma, Malignant Renal Pelvis Neoplasm, Malignant Ureter Neoplasm
- Trial name
- NCT05756569
- Testing
- Biospecimen Collection, Computed Tomography, Enfortumab Vedotin
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- Emory University
Renal Cell Carcinoma, Nonclear Cell
A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With Temsirolimus
1. There is no standard treatment option for non-clear cell renal cell carcinoma (RCC). 2. Patients with non-clear cell RCC is strongly assumed to have benefit from anti-VEGF treatment. 3.
- Conditions
- Renal Cell Carcinoma, Nonclear Cell, Temsirolimus Resistance
- Trial name
- NCT01798446
- Testing
- Axitinib
- Where
- South Korea
- Volunteers
- 41 people
- Sponsor
- Seoul National University Hospital
Clear Cell Renal Cell Carcinoma, Metastatic Malignant Neoplasm in the Bone
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
This phase III trial compares the usual treatment (treatment with ipilimumab and nivolumab followed by nivolumab alone) to treatment with ipilimumab and nivolumab, followed by nivolumab with cabozantinib in patients with…
- Conditions
- Clear Cell Renal Cell Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes, Metastatic Malignant Neoplasm in the Soft Tissue
- Trial name
- NCT03793166
- Testing
- Biospecimen Collection, Bone Scan, Cabozantinib
- Where
- 859 sites in United States, Puerto Rico
- Volunteers
- 1,175 people
- Sponsor
- National Cancer Institute (NCI)
Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Cancer
Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer
This randomized phase II trial studies how well axitinib with or without anti-OX40 antibody PF-04518600 work in treating patients with kidney cancer that has spread to other parts of the body.
- Conditions
- Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Cancer, Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer
- Trial name
- NCT03092856
- Testing
- Anti-OX40 Antibody PF-04518600, Axitinib, Laboratory Biomarker Analysis
- Where
- 9 sites in United States
- Volunteers
- 62 people
- Sponsor
- University of Southern California
Metastatic Clear Cell Renal Cancer
A Phase II Study Investigating Upfront Pazopanib In Metastatic Renal Cancer Renal Cancer (Panther)
The purpose of this study is to investigate if 14 weeks of pazopanib therapy prior to surgery (nephrectomy) is of benefit to patients with metastatic renal cancer. Ninety-five patients will be recruited into his study.
- Trial name
- Panther (NCT01512186)
- Where
- 9 sites in United Kingdom
- Volunteers
- 95 people
- Sponsor
- Queen Mary University of London
Clear Cell Renal Cell Carcinoma
Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma
The purpose of this research is to test the safety of PD-1 inhibitor cemiplimab with or without LAG-3 inhibitor fianlimab, and see what effects (good and bad) of cemiplimab either alone or combined with fianlimab has on patients…
- Trial name
- LAG-BOOST (NCT07223541)
- Testing
- Cemiplimab 350 MG Intravenous Solution, Fianlimab 1600 MG Intravenous Solution
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- University of Oklahoma
Renal Cell Carcinoma Metastatic, Renal Cell Carcinoma Stage IV
Cabozantinib Treatment Prior to Cytoreductive Nephrectomy in Patients With Advanced or Metastatic Renal Cells Cancer
Phase II, multicenter, national, uncontrolled, multicenter, uncontrolled, phase II clinical trial for the evaluation of cabozantinib treatment prior to cytoreductive nephrectomy in patients with advanced or metastatic renal cell…
- Conditions
- Renal Cell Carcinoma Metastatic, Renal Cell Carcinoma Stage IV, Renal Cell Carcinoma Stage III
- Trial name
- NCT06377722
- Testing
- Cabozantinib
- Where
- 8 sites in Spain
- Volunteers
- 18 people
- Sponsor
- Fundacion Oncosur
Renal Cell Carcinoma (RCC), Metastatic Clear Cell Renal Cell Carcinoma
Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical Study
This study is testing a new medicine called AK112 (Yivoximab) for people with advanced kidney cancer that has spread to other parts of the body (metastatic clear cell renal cell carcinoma).
- Trial name
- NCT07488572
- Testing
- Yivoximab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sun Yat-sen University
Renal Cell Carcinoma
A Post Marketing Surveillance As Required By Philippine Food And Drug Administration
This is a post marketing surveillance which determines the safety profile of the product to Filipinos. This is a FDA requirement for registration.
- Trial name
- NCT01781442
- Testing
- Temsirolimus
- Sponsor
- Pfizer
Metastatic Renal Cell Carcinoma
Sutent Rechallenge In mRCC Patients
Retrospective and prospective study in mRCC patients treated with sutent in first line and rechallenged by Sutent in 3rd and 4th line.
- Trial name
- RESUME (NCT01827254)
- Testing
- sunitinib: observational study
- Where
- 18 sites in France
- Volunteers
- 61 people
- Sponsor
- Pfizer
Metastatic Renal Cell Carcinoma
Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer Patients
There is no standard treatment in patients with renal cell carcinoma that was previously treated with VEGF targeted therapies and mTOR inhibitors.So investigators conducted a randomized, open-label, multi-center phase II study to…
- Trial name
- NCT02330783
- Testing
- Bevacizumab, Sorafenib
- Where
- 4 sites in China
- Volunteers
- 106 people
- Sponsor
- Peking University Cancer Hospital & Institute
Clear-cell Metastatic Renal Cell Carcinoma
Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery
Two randomized trials in the cytokine era clearly showed that cytoreductive nephrectomy (CN) had a role in metastatic renal cell carcinoma (mRCC) increasing life expectancy.
- Trial name
- TARIBO (NCT02535351)
- Testing
- sunitinib or pazopanib, Cytoreductive nephrectomy
- Where
- Italy
- Volunteers
- 13 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Advanced Clear Cell Renal Cell Carcinoma, Advanced Papillary Renal Cell Carcinoma
CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer
This phase I trial evaluates the effects of CBM588 in combination with standard therapies, nivolumab and cabozantinib, in treating patients with kidney cancer that has spread to other places in the body (advanced/metastatic).
- Conditions
- Advanced Clear Cell Renal Cell Carcinoma, Advanced Papillary Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma
- Trial name
- NCT05122546
- Testing
- Cabozantinib S-malate, Clostridium butyricum CBM 588 Probiotic Strain, Nivolumab
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- City of Hope Medical Center
Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
This phase II trial tests whether using genetic testing of tumor tissue to select the optimal treatment regimen works in treating patients with clear cell renal cell (kidney) cancer that has spread to other places in the body…
- Conditions
- Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
- Trial name
- NCT05361720
- Testing
- Cabozantinib, Ipilimumab, Nivolumab
- Where
- 6 sites in United States
- Volunteers
- 54 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Solid Tumor, Non Small Cell Lung Cancer
A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors
This is a phase I, First-in-Human (FIH), open-label study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of AB248 as monotherapy OR in combination with pembrolizumab in adult…
- Conditions
- Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT05653882
- Testing
- etakafusp alfa (AB248), pembrolizumab
- Where
- 20 sites in United States
- Volunteers
- 552 people
- Sponsor
- Asher Biotherapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.